Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1570 - Gene expression changes in the immunotherapy targets CTLA4 and LAG3 in right- and left-sided colorectal cancer tissues during preoperative oral uracil and tegafur/leucovorin chemotherapy

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Immunotherapy;  Translational Research;  Colon and Rectal Cancer

Presenters

Sotaro Sadahiro

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

S. Sadahiro1, T. Suzuki1, A. Tanaka1, K. Okada1, G. Saito1, H. miyakita1, H. Nagase2

Author affiliations

  • 1 Surgery, Tokai University, 259-1193 - Isehara/JP
  • 2 Applied Pharmacology Lab., Taiho Pharmaceutical Co., Ltd., 7710194 - Tokushima/JP
More

Resources

Abstract 1570

Background

Oral uracil and tegafur (UFT)/leucovorin (LV) are widely used as a standard adjuvant chemotherapy for colorectal cancer (CRC). On the other hand, immune checkpoint inhibitors such as pembrolizumab are being developed for the treatment of patients with CRC with high microsatellite instability or a mismatch repair deficiency. However, the effects of standard chemotherapy on the expression levels of immunotherapy targets are unknown. In the present study, we examined the gene expression levels of immunotherapy targets in tumor tissues before and after UFT/LV chemotherapy in patients with CRC.

Methods

The subjects were 80 patients with CRC who were scheduled to undergo surgery. UFT (300 mg/m2/day) and LV (75 mg/day) were administered for 2 weeks before surgery. Using an RT-PCR assay, the gene expression levels of four immunotherapy targets, CD274, CTLA4, IDO1 and LAG3, were quantitatively evaluated in paired samples of tumor-biopsy specimens obtained before chemotherapy (pre-samples) and resected-tumor specimens obtained after chemotherapy (post-samples).

Results

In the pre-samples, no differences in the gene expression levels of the four immunotherapy targets were observed between the right- and left-sided colorectal cancer biopsy specimens, but the gene expression levels of LAG3 were significantly higher in elderly patients (≥75 years) than in younger patients (

Conclusions

The increases in the gene expressions of the immunotherapy targets CTLA4 and LAG3 after oral chemotherapy with UFT/LV were specific to left-sided colorectal tumors, suggesting that immunotherapy strategies for patients with CRC after standard chemotherapy should be considered separately for right- and left-sided colorectal tumors.

Clinical trial identification

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.